Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

1.15

Mkt cap

364K

Volume

265K

High

1.16

P/E Ratio

-0.01

52-wk high

898.00

Low

1.09

Div yield

N/A

52-wk low

1.08

iRhythm Technologies shares surged over 20% in pre-market trading following FDA clearance for its Zio AT device. Other notable pre-market movers include Genprex, SRM Entertainment, and TC Biopharm, with significant gains, while companies like IN8bio and DMC Global saw declines.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 11:06 am

Several healthcare stocks experienced significant intraday movements on Monday. Genprex, Inspire Veterinary, and BioVie saw substantial gains, while TC BioPharm, Meihua Intl Medical Techs, and Gritstone Bio faced notable declines.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 4:31 pm

In Wednesday's after-market session, several healthcare stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, MSP Recovery, and TC BioPharm, while 10x Genomics and Trinity Biotech were among the losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 8:31 pm

On Monday, several healthcare stocks experienced significant intraday movements. Scholar Rock Holding (SRRK) saw a massive increase of 324.2%, while LogicMark (LGMK), Cue Biopharma (CUE), Akoya Biosciences (AKYA), WORK Medical Technology (WOK), and iBio (IBIO) also posted gains. Conversely, Trevena (TRVN), Galecto (GLTO), TC BioPharm (TCBP), Virpax Pharmaceuticals (VRPX), Virios Therapeutics (VIRI), and Meihua Intl Medical Techs (MHUA) experienced notable declines.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 4:31 pm

TC BioPharm's shares declined following the announcement of a partnership with Carnegie Mellon University to use AI for donor screening.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 7:05 pm

TC BioPharm Limited is collaborating with Carnegie Mellon University to develop an AI solution for optimizing donor screening and matching in cell therapy. This initiative aims to improve manufacturing yields, production processes, and patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:33 pm

Several healthcare stocks experienced significant price movements in Friday's after-market session. Notable gainers included IGC Pharma, TC BioPharm, and OptiNose, while Gain Therapeutics, Estrella Immunopharma, and Eyenovia were among the losers.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 8:31 pm

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Cardio Diagnostics Holdings, TC BioPharm, and Seres Therapeutics, while Cue Biopharma and enVVeno Medical were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 8:31 pm

TCBP shares are experiencing an uptick following the announcement that the first patient has completed the full dose regimen in the ACHEIVE clinical trial.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 2:44 pm

TC BioPharm (NASDAQ:TCBP) announced that the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial with no adverse events related to TCB008. This milestone in the UK trial involves patients receiving up to four doses of TCB008, with the first patient receiving approximately one billion cells.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.